获得性血友病 中国就医指南

Acquired Hemophilia (AH) is a rare, life-threatening autoimmune bleeding disorder characterized by the spontaneous development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII) in individuals with no prior personal or family history of hemophilia. Unlike congenital hemophilia, AH occurs de novo—typically in older adults—and results in impaired thrombin generation and defective fibrin clot formation. Pathogenesis centers on loss of immune tolerance: autoreactive B cells produce immunoglobulin G (IgG) antibodies that neutralize FVIII activity or accelerate its clearance, leading to markedly prolonged activated partial thromboplastin time (aPTT), undetectable or low FVIII activity (<1–5% of normal), and presence of an FVIII inhibitor confirmed by Bethesda or Nijmegen-Bethesda assay. Approximately 50% of cases are idiopathic; the remainder are associated with underlying conditions including autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus), malignancies (especially lymphoproliferative disorders and solid tumors in elderly patients), pregnancy (postpartum onset), and exposure to certain medications (e.g., interferon-alpha, penicillamine). Epidemiologically, AH has an incidence of 1–1.5 cases per million person-years, with median age at diagnosis of 70–80 years and no significant sex predilection—though slightly higher incidence is reported in women, possibly linked to postpartum cases. Risk factors include advanced age (>65 years), female sex (particularly in postpartum period), autoimmune comorbidity, active malignancy, and chronic inflammatory states. Clinically, patients present with sudden, severe, and often spontaneous bleeding—including extensive subcutaneous hematomas, muscle bleeds, gastrointestinal or urogenital hemorrhage, retroperitoneal bleeding, and, rarely, intracranial hemorrhage. Unlike congenital hemophilia, joint bleeds (hemarthroses) are uncommon. Delayed diagnosis is frequent due to nonspecific symptoms and lack of awareness, contributing to high early mortality (up to 20% within weeks), primarily from uncontrolled hemorrhage or complications of immunosuppressive therapy. Quality of life is profoundly impacted: patients experience acute pain, functional disability, anxiety about recurrent bleeding, treatment-related side effects (e.g., infections, hyperglycemia, hypertension from corticosteroids), hospitalization burden, and psychosocial distress. Long-term survivors may face chronic anemia, organ damage from recurrent bleeds, and persistent fatigue. Early recognition, rapid hemostatic control using bypassing agents (e.g., recombinant activated factor VII or activated prothrombin complex concentrate), and prompt initiation of immunosuppression (prednisone ± cyclophosphamide or rituximab) are critical to survival and functional recovery.

# 获得性血友病（血液科）治疗方案与费用明细

一、非手术/保守治疗

• •一线免疫抑制治疗（适用初发、抗体滴度<5 BU/mL者）：泼尼松（1 mg/kg/d）+环磷酰胺（0.75–1 g/m²/月），疗程3–6个月；费用区间：8,000–22,000元/疗程（含激素、CTX、每月aPTT/FVIII抑制物检测、肝肾功能监测）
• •二线生物制剂（难治/复发/高滴度者）：利妥昔单抗（375 mg/m²×4周），联合小剂量糖皮质激素；费用区间：36,000–52,000元/疗程（含药费、输注护理、CD20检测、感染筛查）
• •旁路治疗支持（急性出血期）：活化凝血酶原复合物（aPCC，FEIBA）或重组活化因子VII（rFVIIa），按体重给药；单次费用：4,500–18,000元（依剂量及出血严重程度）

二、介入/核心治疗

• •血浆置换联合免疫抑制（抗体滴度>20 BU/mL或危及生命出血）：每周2–3次，持续1–3周；全套费用：28,000–45,000元（含术前凝血功能、血型交叉配血、白蛋白补充、置换耗材及监护）

三、特殊复杂方案

• •耐药/复发/合并自身免疫病者：硼替佐米+利妥昔单抗+小剂量地塞米松方案；费用区间：65,000–92,000元/周期（含多发性骨髓瘤相关筛查、神经毒性监测、感染预防）

四、方案快速选择指南

• •预算有限（≤2万元）：首选泼尼松+环磷酰胺保守方案（需规律随访）
• •中等预算（3–6万元）且高滴度者：利妥昔单抗单药方案（疗效明确、安全性优）
• •危重出血或免疫难治者（≥6万元）：血浆置换联合靶向免疫调节，优先三甲血液科诊疗中心实施